



ATC codes: **L01AA09**

Indication	Follicular lymphoma <b>ICD11 code: 2B50.Z</b>
INN	Bendamustine
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > unspecified: 45 mg per 0.5 mL ; 180 mg per 2 mL
EML status history	First added in 2015 ( <b>TRS 994</b> )
Sex	All
Age	Adolescents and adults
Therapeutic alternatives	The recommendation is for this specific medicine
Patent information	Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a>  Read more <b>about patents</b> . 


Tags

Cancer

Wikipedia

[Bendamustine](#) 

DrugBank

[Bendamustine](#) 

## Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, bendamustine was added to the complementary list of the EML for use in treatment protocols for follicular lymphoma. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for follicular lymphoma is attached.

Expert Committee report 

